Nephron recalls sterile glycopyrrolate injection vials due to lack of assurance of sterility. This could lead to infections if used improperly. Check your medication labels for NDC 69374-903-30 and lot GL2004A.
Lack of Assurance of Sterility
Nephron is recalling glycopyrrolate injection syringes that may not be sterile, which could cause infections if used. This is a serious risk for patients receiving the medication.
The injection syringes lack assurance of sterility, meaning they could be contaminated with bacteria or other pathogens. If used, this could lead to infections or serious health complications.
Patients prescribed glycopyrrolate injection by a healthcare provider. Those using the recalled product without proper sterility checks are at highest risk.
Check for Nephron 503B outsourcing facility, NDC 69374-903-30, and lot number GL2004A on the packaging. The product is packaged in 5 x 3 mL pre-filled syringes per carton, 6 per case.
Discard the recalled glycopyrrolate injection syringes if you have them.
No, the product lacks assurance of sterility and could cause infections if used.
Look for NDC 69374-903-30 and lot GL2004A on the packaging.
Discard the product immediately and contact your healthcare provider for alternatives.
We’ve drafted a message you can send Nephron to request your refund or repair — edit it as you like.
Subject: Recall D-1254-2022 — Nephron Nephron Hello, I own a Nephron that is covered by recall D-1254-2022 from Nephron. I’m writing to arrange the remedy described in the recall (a refund, repair, or replacement as applicable). Could you please tell me the next steps to resolve this? Thank you.
Experiences, tips, and questions from readers. Every comment is reviewed before it appears.
No comments yet — be the first to share your experience.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
